Altevax is a Phase 2 clinical-stage biotechnology company developing a pioneering melanin-based immunotherapy platform for cancer treatment.
Its patented technology enhances antigen-specific T-cell immune responses and is compatible with a broad range of peptides, with potential to complement existing immuno-oncology approaches, including anti-PD-1 therapies.
Altevax’s lead program targeting TERT in glioblastoma is currently in Phase 2 clinical development.
The company collaborates with leading clinical institutions, including AP-HP, and is actively fundraising and exploring strategic partnerships to accelerate development.

Altevax

Org chart

Teams

Offices